101598Pre-clinical proof of concept for a new agent in the treatment of ALSClosedCollaborative R&DInnovate UKChronos Therapeutics Ltd, a company spun out of The University of Oxford, has received a grant to study its lead compound RDC5 in the motor neurone disease: Amyotrophic Lateral Sclerosis or ALS. RDC5 has shown very promising results in the company's ChronoscreenTM and in their models of other diseases involving accelerated cell death and neurodegeneration. The grant will enable Chronos to develop models of ALS and test RDC5 in these models. If, as expected RDC5 has positive results in the grant-funded experiments, Chronos expects to raise new finance to move rapidly to clinical trials in ALS with the hope to bring another treatment option to patients with this devastating disease.